Performance of SASDAS (Simplified Axial Spondyloarthritis Disease Activity Score) versus ASDAS in a Post Hoc Analysis of a Randomized Controlled Clinical Trial - ACR Meeting Abstracts
Descrição
Background/Purpose: The Ankylosing Spondylitis Disease Activity Score (ASDAS) assesses axial spondyloarthritis (axSpA) with good internal consistency and discriminative capacity. However, a scientific calculator or electronic application is required for its calculation. SASDAS (simplified ASDAS) is the sum of the ASDAS´s components, which includes C-reactive protein (CRP), and is easy to perform in daily practice. The […]
PDF) Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI
Construct validity and responsiveness of the simplified version of Ankylosing Spondylitis Disease Activity Score (SASDAS) for the evaluation of disease activity in axial spondyloarthritis, Health and Quality of Life Outcomes
Axial spondyloarthritis criteria and modified NY criteria: issues and controversies
PDF) The Journal of Rheumatology Spondyloarthritis During Treatment with Adalimumab Performance of 3 Enthesitis Indices in Patients with Peripheral
Gustavo Citera's research works Instituto de Rehabilitacion Psicofisica, Buenos Aires (INAREPS) and other places
Performance of 3 Composite Measures for Disease Activity in Peripheral Spondyloarthritis
AS Criteria: Diagnosis (ASAS), Disease Activity (ASDAS), Radiographic Progression (mSASSS) - Arthritis Rheumatism
Frontiers The Risk of Cardiovascular Diseases in Axial Spondyloarthritis. Current Insights
The Ankylosing Spondylitis Disease Activity Score (ASDAS) is the recommended instrument in axial SpA. Poll: Do you use the ASDAS for disease activity measurement in axSpA in your clinical practice? A. Yes
Maxime Dougados's research works Université Paris Cité and other places
Video Abstract: Simplified Ankylosing Spondylitis Disease Activity Score ( SASDAS) Versus ASDAS
Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial, Arthritis Research & Therapy
de
por adulto (o preço varia de acordo com o tamanho do grupo)
